Your browser doesn't support javascript.
loading
Next generation radiotheranostics promoting precision medicine.
Pomykala, K L; Hadaschik, B A; Sartor, O; Gillessen, S; Sweeney, C J; Maughan, T; Hofman, M S; Herrmann, K.
Afiliación
  • Pomykala KL; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, Germany.
  • Hadaschik BA; Department of Urology, University Hospital Essen, Essen, Germany.
  • Sartor O; School of Medicine, Tulane University, New Orleans, USA.
  • Gillessen S; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Sweeney CJ; Dana-Farber Cancer Institute, Boston, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
  • Maughan T; Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
  • Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany. Electronic address: ken.herrmann@uk-essen.de.
Ann Oncol ; 34(6): 507-519, 2023 06.
Article en En | MEDLINE | ID: mdl-36924989
ABSTRACT
Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-DOTATATE for neuroendocrine tumors, and 177Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Alemania